Effect of Curcumin on the Viability and Proliferation of Triple-Negative Breast Cancer (MDA-MB-231) Cells

Triple-negative breast cancer is an aggressive subtype of breast cancer characterised by the absence of oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, a phenotype that severely limits targeted treatment options and is associated with poor clinical outcomes. Curcumin, a polyphenolic compound derived from Curcuma longa, has demonstrated broad anticancer properties in preclinical models; however, its cytotoxic activity specifically against triple-negative breast cancer cells (MDA-MB-231) using standardised in vitro methods remains incompletely characterised. This study evaluated the cytotoxic and anti-proliferative effects of curcumin on MDA-MB-231 cells using a cell viability assay and a cell staining assay, with cisplatin included as a validated positive control. Cells were treated with two-fold serial dilutions of curcumin and cisplatin (0.39–100 micromolar) for 72 hours in the viability assay, and with five fixed concentrations of curcumin (3.75, 7.5, 15, 30 and 60 micromolar) for 72 hours in the staining assay. Curcumin produced a concentration-dependent reduction in cell viability, yielding a half-maximal inhibitory concentration of 27.162 ± 11.0765 micromolar. Cisplatin produced a half-maximal inhibitory concentration of 20.267 ± 26.0745 micromolar, confirming assay validity despite greater variability associated with the positive control. In the staining assay, two independent experiments revealed a threshold, rather than a smoothly progressive, concentration-response relationship: reductions in adherent cell survival at 3.75, 7.5, and 15 micromolar were generally modest and largely non-significant relative to untreated control cells (ranging between approximately 86% and 113% survival), whereas treatment at 30 and 60 micromolar produced marked and highly statistically significant reductions in survival in both independent experiments (falling to between approximately 14% and 45% of control values; p < 0.0001). Overall treatment effects were highly significant by one-way analysis of variance in both independent experiments (Experiment 1: F = 92.17, p < 0.0001; Experiment 2: F = 251.2, p < 0.0001). These findings provide robust in vitro evidence that curcumin exerts meaningful, concentration-dependent cytotoxic and anti-proliferative activity against MDA-MB-231 triple-negative breast cancer cells, with an apparent transition from a largely sub-threshold effect to pronounced cytotoxicity occurring between 15 and 30 micromolar, supporting its further evaluation as a candidate anticancer agent.

triple-negative breast cancer; curcumin; cell viability assay; crystal violet assay; cytotoxicity; MDA-MB-231

1. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews Drug Discovery, 20(3), 200–216. https://doi.org/10.1038/s41573-020-00114-z [Google Scholar] [Crossref]

2. Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., O’Shaughnessy, J., Annunziata, C. M., Tagliaferri, M., Hannah, A. L., Cortés, J., Diéras, V., Bachelot, T., & Rugo, H. S. (2021). Sacituzumab govitecan in metastatic triple-negative breast cancer. New England Journal of Medicine, 384(16), 1529–1541. https://doi.org/10.1056/NEJMoa2028485 [Google Scholar] [Crossref]

3. Bareche, Y., Venet, D., Ignatiadis, M., Aftimos, P., Piccart, M., Rothe, F., & Sotiriou, C. (2018). Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Annals of Oncology, 29(4), 895–902. https://doi.org/10.1093/annonc/mdy024 [Google Scholar] [Crossref]

4. Bhatt, A., Bhatt, D. L., & Shah, S. (2022). Curcumin and its role in modulating the PI3K/Akt/mTOR pathway in triple-negative breast cancer: A review. Frontiers in Oncology, 12, 924814. https://doi.org/10.3389/fonc.2022.924814 [Google Scholar] [Crossref]

5. Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022). Treatment landscape of triple-negative breast cancer: Expanded options, evolving needs. Nature Reviews Clinical Oncology, 19(2), 91–113. https://doi.org/10.1038/s41571-021-00565-2 [Google Scholar] [Crossref]

6. Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhatt, D. L., Biganzoli, L., Buyse, M. E., Cardoso, M. J., Carey, L. A., Cortés, J., El Saghir, N. S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P. A., ... Winer, E. P. (2022). 6th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 6). Annals of Oncology, 33(2), 117–140. https://doi.org/10.1016/j.annonc.2021.10.010 [Google Scholar] [Crossref]

7. Cortés, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S.-A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., Holgado, E., Iwata, H., Masuda, N., Otero, M. T., Perez-Garcia, J., Pluard, T. J., Price, G. L., Adamchuk, G., Dai, Z., Huang, C.-S., ... Schmid, P. (2021). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355). The Lancet, 396(10265), 1817–1828. https://doi.org/10.1016/S0140-6736(20)32531-9 [Google Scholar] [Crossref]

8. Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019). Breast cancer. Nature Reviews Disease Primers, 5(1), 66. https://doi.org/10.1038/s41572-019-0111-2 [Google Scholar] [Crossref]

9. Kunnumakkara, A. B., Hegde, M., Parama, D., Girisa, S., Kumar, A., Daimary, U. D., Garodia, P., Yenisetti, S. C., Oommen, O. V., & Aggarwal, B. B. (2023). Role of turmeric and curcumin in prevention and treatment of chronic diseases: Lessons learned from clinical trials. ACS Pharmacology & Translational Science, 6(4), 447–518. https://doi.org/10.1021/acsptsci.2c00012 [Google Scholar] [Crossref]

10. Lambertini, M., Santoro, L., Del Mastro, L., Nguyen, B., Livraghi, L., Ugolini, D., Peccatori, F. A., & Azim, H. A. (2021). Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis. European Journal of Cancer, 142, 95–107. https://doi.org/10.1016/j.ejca.2020.10.017 [Google Scholar] [Crossref]

11. Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., Gonzalez-Ericsson, P. I., Sanders, M. E., Zhang, B., Pietenpol, J. A., & Chen, X. S. (2021). Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature Communications, 12(1), 6276. https://doi.org/10.1038/s41467-021-26502-6 [Google Scholar] [Crossref]

12. Liu, W., Tang, H., Dai, X., & Tian, C. (2022). Curcumin’s anti-breast-cancer effects: A meta-analysis of preclinical studies. Frontiers in Oncology, 11, 739316. https://doi.org/10.3389/fonc.2021.739316 [Google Scholar] [Crossref]

13. Makovec, T. (2019). Cisplatin and beyond: Molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiology and Oncology, 53(2), 148–158. https://doi.org/10.2478/raon-2019-0018 [Google Scholar] [Crossref]

14. Moballegh Nasery, M., Abadi, B., Poormoghadam, D., Zarrabi, A., Keyhanvar, P., Khanbabaei, H., Ashrafizadeh, M., Mohammadinejad, R., Tavakol, S., & Sethi, G. (2020). Curcumin delivery mediated by bio-based nanoparticles: A review. Molecules, 25(3), 689. https://doi.org/10.3390/molecules25030689 [Google Scholar] [Crossref]

15. Nair, K. L., Thulasidasan, A. K. T., Deepa, G., Anto, R. J., & Kumar, G. S. V. (2020). Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination index in triple negative breast cancer cells. Cancers, 12(3), 713. https://doi.org/10.3390/cancers12030713 [Google Scholar] [Crossref]

16. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285 [Google Scholar] [Crossref]

17. Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., Wu, W., Goessl, C., Runswick, S., & Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523–533. https://doi.org/10.1056/NEJMoa1706450 [Google Scholar] [Crossref]

18. Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Foukakis, T., Fasching, P. A., Cardoso, F., Untch, M., Jia, L., Karantza, V., Zhao, J., Aktan, G., ... O’Shaughnessy, J. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine, 382(9), 810–821. https://doi.org/10.1056/NEJMoa1910549 [Google Scholar] [Crossref]

19. Shehzad, A., Lee, J., & Lee, Y. S. (2015). Curcumin in various cancers. BioFactors, 39(1), 56–68. https://doi.org/10.1002/biof.1068 [Google Scholar] [Crossref]

20. Shiovitz, S., & Korde, L. A. (2020). Genetics of breast cancer: A topic in evolution. Human Molecular Genetics, 24(R1), R1–R5. https://doi.org/10.1093/hmg/ddv329 [Google Scholar] [Crossref]

21. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48. https://doi.org/10.3322/caac.21763 [Google Scholar] [Crossref]

22. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660 [Google Scholar] [Crossref]

23. Tchounwou, P. B., Dasari, S., Noubissi, F. K., Ray, P., & Kumar, S. (2021). Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. Journal of Experimental Pharmacology, 13, 303–328. https://doi.org/10.2147/JEP.S267383 [Google Scholar] [Crossref]

24. Tung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., Cousins, L. M., Beck, J. T., Stearns, V., Eisen, A., Hwang, J. H., Mayer, E. L., Pegram, M., Gerber, D. E., Sabbatini, P., ... Garber, J. E. (2020). TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. Journal of Clinical Oncology, 38(36), 4274–4282. https://doi.org/10.1200/JCO.20.02151 [Google Scholar] [Crossref]

25. Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: A review. JAMA, 321(3), 288–300. https://doi.org/10.1001/jama.2018.19323 [Google Scholar] [Crossref]

26. Yedjou, C. G., Sims, J. N., Miele, L., Noubissi, F., Lowe, L., Fonseca, D. D., Tchounwou, P. B., & Bienvenu, J. (2019). Health and racial disparity in breast cancer. Advances in Experimental Medicine and Biology, 1152, 31–49. https://doi.org/10.1007/978-3-030-20301-6_3 [Google Scholar] [Crossref]

27. Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020). Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Research, 22(1), 61. https://doi.org/10.1186/s13058-020-01296-5 [Google Scholar] [Crossref]

• Public Governance Quality and Tax Compliance of SMEs in North-East Nigeria
• The Influence of Conflict Resolution on Job Commitment of Non- Teaching Staff in Public Universities in Southwest, Nigeria